PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32931814-7	2020	Next, the blockade of ERK1/2 pathway by SL-327, a selective MEK1/2 inhibitor, was checked for anxiolytic action.	SL 327	40-46	mitogen-activated protein kinase 3	Mus musculus	22-28	
32931814-11	2020	Co-administration of subeffective doses of SL-327 and diazepam induces anxiolysis, which is CaMKII-independent and correlates to selectively decreased phosphoactive ERK1/2 in the hippocampus.	SL 327	43-49	mitogen-activated protein kinase 3	Mus musculus	165-171	
19402951-3	2009	The intervention group received the ERK1/2 signaling pathway inhibitor SL327 before the pilocarpine injection.	SL 327	71-76	mitogen-activated protein kinase 3	Mus musculus	36-42	
30104581-7	2018	Systemic injection of SL327 (an inhibitor of MEK1/2 that also blocks its downstream signal ERK1/2) prior to RS rescued the working memory impairments and the increased p-ERK1/2 while normalizing the expression of Egr1.	SL 327	22-27	mitogen-activated protein kinase 3	Mus musculus	91-97	
30104581-7	2018	Systemic injection of SL327 (an inhibitor of MEK1/2 that also blocks its downstream signal ERK1/2) prior to RS rescued the working memory impairments and the increased p-ERK1/2 while normalizing the expression of Egr1.	SL 327	22-27	mitogen-activated protein kinase 3	Mus musculus	170-176	
28356400-4	2017	The functional role of the ERK1/2 pathway activation during sexual behaviour was explored with the administration of a MEK inhibitor, SL-327 (30 mg/kg, i.p.	SL 327	134-140	mitogen-activated protein kinase 3	Mus musculus	27-33	
23012487-6	2012	Inhibition of ERK1/2 activation 2 hr after AA injection by subcutaneous (sc) injection of the mitogen-activating extracellular kinase (MEK) inhibitor, SL327, had no effect on the nocifensive responses, but did attenuate anxiety-like behavior, as determined by elevated plus-maze and open-field testing results.	SL 327	151-156	mitogen-activated protein kinase 3	Mus musculus	14-20	
20739576-9	2010	Additionally, systemic MEK inhibition with SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1.	SL 327	43-48	mitogen-activated protein kinase 3	Mus musculus	211-215	
20739576-9	2010	Additionally, systemic MEK inhibition with SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile) attenuated formalin-induced spontaneous behaviors similarly in wild-type and ERK1 KO mice, indicating that unrelated signaling pathways do not functionally compensate for the loss of ERK1.	SL 327	43-48	mitogen-activated protein kinase 3	Mus musculus	317-321	
30003929-10	2019	SL-327 (a MEK inhibitor) augmented KET sleep, further indicating the relevance of reduced p-ERK1/2 in KET-induced hypnosis.	SL 327	0-6	mitogen-activated protein kinase 3	Mus musculus	92-98	
25181481-6	2014	The nonselective protein tyrosine kinase inhibitors genistein and AG490 as well as the selective extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitors PD98059 and SL327 suppressed the mGluR1-mediated current responses.	SL 327	171-176	mitogen-activated protein kinase 3	Mus musculus	97-138	
25181481-6	2014	The nonselective protein tyrosine kinase inhibitors genistein and AG490 as well as the selective extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitors PD98059 and SL327 suppressed the mGluR1-mediated current responses.	SL 327	171-176	mitogen-activated protein kinase 3	Mus musculus	140-146	
21394501-7	2012	Pharmacological inhibition of ERK1/2 by PD98059 and SL327 restored the anti-invasion effects of mTOR inhibition in vitro.	SL 327	52-57	mitogen-activated protein kinase 3	Mus musculus	30-36	
17596448-7	2007	Thus, pharmacological inactivation of ERK1/2 achieved using SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile), an inhibitor of the mitogen-activated kinase/ERK kinase, MEK, during chronic L-DOPA treatment counteracts the induction dyskinesia.	SL 327	60-65	mitogen-activated protein kinase 3	Mus musculus	38-44	
17907844-4	2007	To determine whether ERK 1/2 plays a role in this enhancement, a dose of SL327 (a selective, systemic ERK 1/2 inhibitor) that is subthreshold for inhibiting contextual fear conditioning was coadministered with nicotine prior to training, testing, or both training and testing of contextual fear conditioning in C57BL/6 mice.	SL 327	73-78	mitogen-activated protein kinase 3	Mus musculus	102-109	
17596448-7	2007	Thus, pharmacological inactivation of ERK1/2 achieved using SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile), an inhibitor of the mitogen-activated kinase/ERK kinase, MEK, during chronic L-DOPA treatment counteracts the induction dyskinesia.	SL 327	67-149	mitogen-activated protein kinase 3	Mus musculus	38-44	
15305880-3	2004	Moreover, the ability of haloperidol and eticlopride to stimulate phosphorylation at both seryl residues is prevented by treatment with SL327, a compound that blocks activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2).	SL 327	136-141	mitogen-activated protein kinase 3	Mus musculus	236-242	
16504549-5	2006	In the present study, in order to investigate the involvement of MAPKs in memory reconsolidation processes we administered immediately after retrieval, different doses of SL327 (an inhibitor of MEK, a kinase that activates both ERK1 and ERK2) both in C57BL/6 (C57) mice and ERK1 mutant mice tested in a fear conditioning task.	SL 327	171-176	mitogen-activated protein kinase 3	Mus musculus	228-232	
16504549-5	2006	In the present study, in order to investigate the involvement of MAPKs in memory reconsolidation processes we administered immediately after retrieval, different doses of SL327 (an inhibitor of MEK, a kinase that activates both ERK1 and ERK2) both in C57BL/6 (C57) mice and ERK1 mutant mice tested in a fear conditioning task.	SL 327	171-176	mitogen-activated protein kinase 3	Mus musculus	274-278	
16504549-7	2006	Moreover, SL327 administration impaired memory reconsolidation also in ERK1 mutant mice.	SL 327	10-15	mitogen-activated protein kinase 3	Mus musculus	71-75